UBS Group cut shares of Ambu A/S (OTCMKTS:AMBBY – Free Report) from a strong-buy rating to a hold rating in a research report report published on Tuesday morning,Zacks reports.
Ambu A/S Stock Performance
Shares of AMBBY opened at $10.25 on Tuesday. Ambu A/S has a 12-month low of $8.54 and a 12-month high of $16.78. The company has a current ratio of 2.92, a quick ratio of 1.73 and a debt-to-equity ratio of 0.08. The company has a market cap of $2.41 billion, a PE ratio of 34.17 and a beta of 0.93. The stock has a 50-day moving average price of $10.73 and a 200-day moving average price of $10.46.
Ambu A/S (OTCMKTS:AMBBY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 25th. The company reported $0.09 earnings per share for the quarter. The company had revenue of $255.12 million for the quarter. Ambu A/S had a net margin of 8.18% and a return on equity of 8.56%.
Ambu A/S Company Profile
Ambu A/S is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. The company focuses on reducing the need to reprocess reusable equipment while supporting clinical procedures in areas such as endoscopy, anesthesia and patient monitoring.
Ambu’s product portfolio includes disposable endoscopes and related visualization systems, airway management products, anesthesia equipment and devices used for patient monitoring and diagnostics.
Featured Stories
- Five stocks we like better than Ambu A/S
- This Gold ETF Turns a Non-Yielding Asset Into Monthly Income—But There’s a Catch
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
